Publicaciones en colaboración con investigadores/as de Hospital Universitari de Bellvitge (24)

2024

  1. Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/ MINOVA Study)

    Clinical Cancer Research, Vol. 30, Núm. 1, pp. 176-186

2023

  1. IASLC Lung Cancer Staging Project: The New Database to Inform Revisions in the Ninth Edition of the TNM Classification of Lung Cancer

    Journal of Thoracic Oncology, Vol. 18, Núm. 5, pp. 564-575

  2. Recommendations for optimizing the use of cytology in the diagnosis and management of patients with lung cancer

    Revista Espanola de Patologia, Vol. 56, Núm. 1, pp. 58-68

2022

  1. A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα and IL-1β

    Cancer Discovery, Vol. 12, Núm. 9, pp. 2140-2157

  2. Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer

    Journal for immunotherapy of cancer, Vol. 10, Núm. 12

2021

  1. Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402)

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 6, pp. 586-598

  2. Pazopanib as Second-line Antiangiogenic Treatment in Metastatic Renal Cell Carcinoma After Tyrosine Kinase Inhibitor (TKI) Failure: A Phase 2 Trial Exploring Immune-related Biomarkers for Testing in the Post-immunotherapy/TKI Era

    European urology oncology, Vol. 4, Núm. 3, pp. 502-505

2020

  1. Comprehensive analysis of SWI/SNF inactivation in lung adenocarcinoma cell models

    Cancers, Vol. 12, Núm. 12, pp. 1-14

  2. Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors

    Annals of Oncology, Vol. 31, Núm. 2, pp. 274-282

  3. The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor Descriptors for Non–Small Cell Lung Cancer

    Journal of Thoracic Oncology, Vol. 15, Núm. 3, pp. 344-359

2019

  1. EUS-guided tissue acquisition in the study of the adrenal glands: Results of a nationwide multicenter study

    PLoS ONE, Vol. 14, Núm. 6

  2. Inhibitor of differentiation-1 sustains mutant KRAS-driven progression, maintenance, and metastasis of lung adenocarcinoma via regulation of a FOSL1 network

    Cancer Research, Vol. 79, Núm. 3, pp. 625-638

  3. YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib

    American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899

2018

  1. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis

    The Lancet Respiratory Medicine, Vol. 6, Núm. 10, pp. 771-781

  2. KRAS oncogene in non-small cell lung cancer: Clinical perspectives on the treatment of an old target

    Molecular Cancer, Vol. 17, Núm. 1

  3. Mechanisms Involved in the Remyelinating Effect of Sildenafil

    Journal of Neuroimmune Pharmacology, Vol. 13, Núm. 1, pp. 6-23

2017

  1. Genomic profiling of patient-derived xenografts for lung cancer identifies B2M inactivation impairing immunorecognition

    Clinical Cancer Research, Vol. 23, Núm. 12, pp. 3203-3213

2016

  1. Identification of new markers of recurrence in patients with unprovoked deep vein thrombosis by gene expression profiling: the retro study

    European Journal of Haematology, Vol. 97, Núm. 2, pp. 128-136

2014

  1. MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1

    Cancer Discovery, Vol. 4, Núm. 3, pp. 293-303

2009

  1. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome

    Journal of Cell Biology, Vol. 187, Núm. 7, pp. 1083-1099